Abstract: The invention provides certain N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or develop of a disease or condition. In some embodiments, the disease or condition is selected from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy.

Abstract: The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.

Abstract: Disclosed herein are an ion-dissociative functional compound, a method for production thereof, an ionic conductor, and an electrochemical device, the ion-dissociative functional compound being thermally and chemically stable under the condition required of fuel cells and being suitable for use as a material such as protonic conductor in fuel cells. The proton-dissociative functional compound shown in FIG. 1A is composed of a fullerene C60 molecule and about 10 sulfonic acid groups —SO3H as proton-dissociative groups each attached to the fullerene through a difluoromethane group —CF2—. The proton-dissociative functional compound shown in FIG. 1B is composed of fullerene molecules three-dimensionally connected to each other through a linking group —CF2SO2NHSO2CF2—. It contains, as the proton-dissociative group, sulfoneimide groups —SO2NHSO2— and sulfoneamide groups —SO2H2 in addition to sulfonic acid groups.

Abstract: Sulfohydroxamic acid diarylamines of formula (I), in which the variables are as defined in the claims, are inhibitors of MEK and are effective in the treatment of proliferative diseases, cancer, stroke, heart failure, xenograft rejection, arthritis, cystic fibrosis, hepatomegaly, cardiomegaly, Alzheimer's disease, complications of diabetes, septic shock, and viral infection.

Abstract: Compounds of formula (I) wherein R is hydroxy, hydrogen, alkenyl, alkynyl or aryl, and R1 is aryl or heteroaryl, are useful in the treatment and prophylaxis of conditions mediated by CD23 or TNF.